newsfilter
← Latest News
PR Newswire·

Provention Bio Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022

RED BANK, N.J., June 30, 2022 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the U.S. Food and Drug Administration (F